In 2020, scientists in the United Kingdom, began an innovative trial to test a drug made from antibody created by vaccine maker AstraZeneca. They hoped this drug known as AZD7442 will provide instant and long lasting protection against COVID-19.
The trial was separated into two studies which are being run by the University College London Hospitals NHS Trust (UCLH). The UCLH has declared that these antibodies are Long Acting AntiBody (LAAB).
